NCT05588609 2025-09-18Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined CancersMerus B.V.Phase 2 Terminated13 enrolled
NCT02912949 2025-04-29A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)Partner Therapeutics, Inc.Phase 2 Active not recruiting250 enrolled 1 FDA
NCT03321981 2024-03-07MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.Merus B.V.Phase 2 Completed105 enrolled 23 charts